Praxis Precision Medicines Inc

NASDAQ:PRAX   3:59:50 PM EDT
2.49
-0.09 (-3.49%)
Products, Regulatory

Praxis Precision Medicines Provides Updates On Clinical Stage Pediatric Epilepsy Programs

Published: 09/07/2022 11:43 GMT
Praxis Precision Medicines Inc (PRAX) - Praxis Precision Medicines Provides Updates on Clinical Stage Pediatric Epilepsy Programs.
Praxis Precision Medicines - to Start Prax-222 Embrave Clinical Study for Treatment of Pediatric Patients With Early-seizure-onset Scn2a Dee.
Praxis Precision Medicines - to Start Prax-562 Phase 2 Study for Treatment of Pediatric Patients With Scn2a and Scn8a Dees Outside of U.S. Before End of 2022.
Praxis Precision Medicines Inc - Prax-562 Has Been Dosed in Over 130 Healthy Volunteers in Completed and Ongoing Studies.
Praxis Precision - Initiated Discussions With FDA for Prax-562 for Clarification About Pre-clinical and Clinical Data Packages for Clinical Hold Correspondence.
Praxis Precision Medicines - Topline Results for Prax-562 Phase 2 Study for Treatment of Pediatric Patients With Scn2a and Scn8a Dees Expected in 2023.